Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
Because end-stage renal disease patients undergoing hemodialysis frequently take acid suppressants for the treatment or prevention of gastrointestinal diseases, it is important to clarify the drug-interactions between acid suppressants and phosphate binders on the control of serum phosphate levels....
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/0886022X.2020.1803085 |
| _version_ | 1818848973556809728 |
|---|---|
| author | Hitoshi Minakuchi Tadashi Yoshida Noriko Kaburagi Teppei Fujino Sho Endo Tomoko Yamashita Takemitsu Norimasa Yamashita Hiroshi Itoh Mototsugu Oya |
| author_facet | Hitoshi Minakuchi Tadashi Yoshida Noriko Kaburagi Teppei Fujino Sho Endo Tomoko Yamashita Takemitsu Norimasa Yamashita Hiroshi Itoh Mototsugu Oya |
| author_sort | Hitoshi Minakuchi |
| collection | DOAJ |
| description | Because end-stage renal disease patients undergoing hemodialysis frequently take acid suppressants for the treatment or prevention of gastrointestinal diseases, it is important to clarify the drug-interactions between acid suppressants and phosphate binders on the control of serum phosphate levels. In the present study, we examined whether the phosphate-lowering effects of three phosphate binders, lanthanum carbonate (LC), ferric citrate hydrate (FCH), and sucroferric oxyhydroxide (SFOH), were affected by proton pump inhibitors (PPIs) in maintenance hemodialysis patients. Laboratory data for 71 patients who had been newly prescribed one of the three phosphate binders were examined. LC at a dosage of 500 ± 217 mg/day significantly decreased serum phosphate levels by −18% in the absence of a PPI (n = 9), while a dosage of 700 ± 230 mg/day only decreased it by −3% in the presence of a PPI (n = 10). Thus, the efficacy of LC in reducing serum phosphate levels was significantly hindered by the presence of PPIs. FCH significantly decreased serum phosphate levels by −18% in the absence of a PPI (n = 7, FCH: 571 ± 189 mg/day) and by −17% in the presence of a PPI (n = 20, FCH: 638 ± 151 mg/day). The decrease in serum phosphate levels by SFOH (393 ± 197 mg/day) was −7% in the absence of a PPI (n = 7), and SFOH at a dosage of 556 ± 316 mg/day significantly decreased serum phosphate levels by −13% in the presence of a PPI (n = 18). These results suggest that the phosphate-lowering effect of LC, but not of FCH or SFOH, is diminished in the presence of PPIs in hemodialysis patients. |
| first_indexed | 2024-12-19T06:25:51Z |
| format | Article |
| id | doaj.art-5c1433737ea3491db5a3d9d7598aee3c |
| institution | Directory Open Access Journal |
| issn | 0886-022X 1525-6049 |
| language | English |
| last_indexed | 2024-12-19T06:25:51Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj.art-5c1433737ea3491db5a3d9d7598aee3c2022-12-21T20:32:34ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492020-01-0142179980610.1080/0886022X.2020.18030851803085Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patientsHitoshi Minakuchi0Tadashi Yoshida1Noriko Kaburagi2Teppei Fujino3Sho Endo4Tomoko Yamashita Takemitsu5Norimasa Yamashita6Hiroshi Itoh7Mototsugu Oya8Apheresis and Dialysis Center, Keio University School of MedicineApheresis and Dialysis Center, Keio University School of MedicineSeigakai Shibuya Station ClinicSeigakai Yoyogi Station ClinicApheresis and Dialysis Center, Keio University School of MedicineSeigakai Shibuya Station ClinicSeigakai Shibuya Station ClinicDepartment of Internal Medicine, Keio University School of MedicineApheresis and Dialysis Center, Keio University School of MedicineBecause end-stage renal disease patients undergoing hemodialysis frequently take acid suppressants for the treatment or prevention of gastrointestinal diseases, it is important to clarify the drug-interactions between acid suppressants and phosphate binders on the control of serum phosphate levels. In the present study, we examined whether the phosphate-lowering effects of three phosphate binders, lanthanum carbonate (LC), ferric citrate hydrate (FCH), and sucroferric oxyhydroxide (SFOH), were affected by proton pump inhibitors (PPIs) in maintenance hemodialysis patients. Laboratory data for 71 patients who had been newly prescribed one of the three phosphate binders were examined. LC at a dosage of 500 ± 217 mg/day significantly decreased serum phosphate levels by −18% in the absence of a PPI (n = 9), while a dosage of 700 ± 230 mg/day only decreased it by −3% in the presence of a PPI (n = 10). Thus, the efficacy of LC in reducing serum phosphate levels was significantly hindered by the presence of PPIs. FCH significantly decreased serum phosphate levels by −18% in the absence of a PPI (n = 7, FCH: 571 ± 189 mg/day) and by −17% in the presence of a PPI (n = 20, FCH: 638 ± 151 mg/day). The decrease in serum phosphate levels by SFOH (393 ± 197 mg/day) was −7% in the absence of a PPI (n = 7), and SFOH at a dosage of 556 ± 316 mg/day significantly decreased serum phosphate levels by −13% in the presence of a PPI (n = 18). These results suggest that the phosphate-lowering effect of LC, but not of FCH or SFOH, is diminished in the presence of PPIs in hemodialysis patients.http://dx.doi.org/10.1080/0886022X.2020.1803085drug interactionend-stage renal diseasephosphatephosphate bindersproton pump inhibitors |
| spellingShingle | Hitoshi Minakuchi Tadashi Yoshida Noriko Kaburagi Teppei Fujino Sho Endo Tomoko Yamashita Takemitsu Norimasa Yamashita Hiroshi Itoh Mototsugu Oya Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients Renal Failure drug interaction end-stage renal disease phosphate phosphate binders proton pump inhibitors |
| title | Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients |
| title_full | Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients |
| title_fullStr | Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients |
| title_full_unstemmed | Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients |
| title_short | Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients |
| title_sort | proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate but not of ferric citrate hydrate or sucroferric oxyhydroxide in hemodialysis patients |
| topic | drug interaction end-stage renal disease phosphate phosphate binders proton pump inhibitors |
| url | http://dx.doi.org/10.1080/0886022X.2020.1803085 |
| work_keys_str_mv | AT hitoshiminakuchi protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT tadashiyoshida protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT norikokaburagi protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT teppeifujino protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT shoendo protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT tomokoyamashitatakemitsu protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT norimasayamashita protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT hiroshiitoh protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients AT mototsuguoya protonpumpinhibitorsmayhinderhypophosphatemiceffectoflanthanumcarbonatebutnotofferriccitratehydrateorsucroferricoxyhydroxideinhemodialysispatients |